Table 2.
Patient demographics and baseline clinical characteristics.
| Demographic variable | All patients N = 48 |
Evaluable patients N = 45 |
|---|---|---|
| Age, median (range), years | 56.5 (26–86) | 54.0 (26–86) |
| Age category, n (%) | ||
| 18 to <65 years | 32 (66.7) | 31 (68.9) |
| ≥65 years | 16 (33.3) | 14 (31.1) |
| ≥75 years | 4 (8.3) | 4 (8.9) |
| Sex, n (%) | ||
| Male | 37 (77.1) | 36 (80.0) |
| Female | 11 (22.9) | 9 (20.0) |
| Race, n (%) | ||
| White | 23 (47.9) | 21 (46.7) |
| Asian | 12 (25.0) | 12 (26.7) |
| Unknown | 6 (12.5) | 5 (11.1) |
| Other | 6 (12.5) | 6 (13.3) |
| Black or African American | 1 (2.1) | 1 (2.2) |
| Ethnicity, n (%) | ||
| East Asian | 10 (20.8) | 10 (22.2) |
| Other | 16 (33.3) | 14 (31.1) |
| Not reported | 14 (29.2) | 13 (28.9) |
| Unknown | 3 (6.3) | 3 (6.7) |
| Southeast Asian | 2 (4.2) | 2 (4.4) |
| Hispanic or Latino | 3 (6.3) | 3 (6.7) |
| ECOG performance status, n (%) | ||
| 0 | 36 (75.0) | 33 (73.3) |
| 1 | 12 (25.0) | 12 (26.7) |
| No. of prior TKIs | ||
| 1a | 8 (16.7) | 8 (17.8) |
| 2 | 15 (31.3) | 14 (31.1) |
| 3 | 17 (35.4) | 16 (35.6) |
| ≥4 | 8 (16.7) | 7 (15.6) |
| Individual prior TKIs | ||
| Bosutinib | 3 (6.3) | 2 (4.4) |
| Dasatinib | 33 (68.8) | 33 (73.3) |
| Imatinib | 27 (56.3) | 25 (55.6) |
| Nilotinib | 26 (54.2) | 23 (51.1) |
| Ponatinib | 29 (60.4) | 26 (57.8) |
| Radotinib | 4 (8.3) | 4 (8.9) |
| Reason for discontinuation of last dose of ponatinib | ||
| Intolerance | 9 (31.0) | 7 (26.9) |
| Resistance | 14 (48.3) | 13 (50.0) |
| Other | 6 (20.7) | 6 (23.1) |
| Mutations at screening, n (%) | ||
| T315I alone | 46 (95.8) | 43 (95.6) |
| T315I and E255K | 1 (2.1) | 1 (2.2) |
| T315I and E355G | 1 (2.1) | 1 (2.2) |
| BCR::ABL1IS at screening, n (%) | ||
| >0.01% to 0.1% | 0 | 0 |
| >0.1% to 1% | 8 (16.7) | 8 (17.8) |
| >1% to 10% | 11 (22.9) | 11 (24.4) |
| >10% | 26 (54.2) | 26 (57.8) |
| Atypical /e1a2/unknown transcriptsb | 3 (6.3) | 0 |
ECOG Eastern Cooperative Oncology Group, TKI tyrosine kinase inhibitor.
aPrior TKIs included dasatinib (n = 5), nilotinib (n = 2), and radotinib (n = 1).
be19a2 transcript, e13a3 (b2a3) transcript, no transcript detected (n = 1, each).